Tags: Drug.
LY-320135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB1. It was developed by Eli Lilly and Company in the 1990s. LY-320135 displays fairly good selectivity with a binding affinity for CB1 around 70x stronger than for CB2 but both its potency and selectivity are modest compared to newer agents and at higher doses it also binds to a range of non-cannabinoid receptors.
